Healthcare Executive Marc Beer Is Tapped To Head LumeNXT’s Board Of Directors

Marc Beer is an executive in the healthcare industry. His latest venture is Renovia, a company he co-founded with Dr. Ramon Iglesias and Yolanda Lorié. This company, which was founded in August 2016, creates medical devices and services for women who suffer from pelvic floor disorder. This is the latest in a series of healthcare companies he has founded or co-founded over the past 30 years.

One of his earliest companies was Good Start Genetics, Inc. where he was the founding chairman of the board of directors. Marc Beer’s other companies include Minerva Neurosciences, Inc., Genzyme, and ViaCell. He is a graduate of Ohio’s Miami University where he earned a bachelor’s degree.

In early 2019, Marc Beer was selected to join the board of LumeNXT, Inc., as its new chairman. This is a private venture that has developed a line of illumination devices for surgeons. The devices are designed to be used during minimally invasive surgeries. He was chosen due to his extensive experience launching and growing medical devices firms. He was also chosen given his past success as a leader in the industry.

Marc Beer says that he was impressed with the team at LumeNXT when he met them. LumeNXT is a team of surgeons and engineers who used their collective skills to solve a problem doctors have in the surgical room. He said that their technology will give surgeons a way to do surgery in a safer and more effective manner. This is especially important as there are more minimally invasive surgeries than ever today and the practice is expected to keep growing.

Their illumination device has a number of advantages. It incorporates a heat reduction device that reduces the chances of a patient suffering burns. It also gives surgeons a way to be even more precise when cutting a patient open and then sealing the cut shut. Additionally, their illumination devices are low-cost and can be disposed of after a surgery has been completed.

Paul Rhyne is one of the co-founders of LumeNXT. He said that Marc Beer has shown he knows how to build a successful startup and lead it through multiple growth phases. He and his team are excited to work with him so that LumeNXT will be as successful as possible. Their products are going to be releasing in the United States as well as globally, something he also has a great deal of experience with. Learn more: https://ideamensch.com/marc-beer/

 

Carsten Thiel

Recently, EUSA Pharma, a Global pharmaceutical company that focusses on oncology and rare disease has announced the appointment of Carsten Thiel as President Europe and Darrel P. Cohen as Head of Clinical Development. The company (EUSA) was founded in March 2015 and had extensive commercial operations in the United States and Europe together with the direct presence in select markets across the globe.

Carsten Thiel is a Pharmaceutical and Biopharmaceutical expert. He was born in Berlin. He remained in Berlin which was then divided and excelled in his studies and ended up studying Chemistry in Malbrook. He left his native country to attend the University of Bristol in the southwestern UK in a bid to gather insight on the Anglo-Saxon education system. There, he studied Organic Chemistry, where he received a Bachelor of Science degree upon completion of his course. His desire to get into the pharmaceutical world of innovation came through with Hoffman La-Roche, a ground-breaking biotechnology firm after completion of his formal education.

Appointment of veterans in the pharmaceutical world in new roles created will help strengthen the management that is senior leadership. The duo brings with them a high level of pharmaceutical experience. Carsten Thiel will lead commercial infrastructure in Europe while Dr. Cohen will lead the worldwide late-stage Clinical Development activities.

Carsten Thiel has 27 years of commercial experience coming to EUSA Pharma. This is in addition to the Ph.D. that he holds in Molecular Biology and Biochemistry from Germany’s Max Plancks Institute. Dr. Cohen, on the other hand, has 20 years of experience in Clinical Development in the Pharmaceutical Industry. Dr. Cohen is joining EUSA Pharma from Pfizer’s global oncology Organization, where he had the rank of Vice President, Clinical Development Leader after previously leading Clinical development for numerous successful oncology products.

EUSA Chief Executive Officer welcomed the duo highlighting the skills and experience that they bring to the company. The knowledge and expertise would help the company as it expands in Europe, emerging markets, and the United States. Click here to learn more

Marc Beer: The answer to Women’s Healthcare

Marc Beer is a major player in the women’s healthcare industry and is also the chairman or Lume NXT. Lume NXT is a company that creates illumination devices for surgeons. With better illumination, the surgeons have more effective means of working and that could be the decisive equipment between life and death. For surgery to be successful, everything has to go as planned and as effective as possible lumeNXT. Appointing Marc Beer as the chairman only goes to show that they are after the right results, Learn more: https://renoviainc.com/leadership/

Marc Beer has a track record of excellence, with over 25 years in the industry. Before this, he was the co-founder of Renovia, and the company specialized in helping women with pelvic abnormalities. His company started when a gynecologist called him to tell him of the troubles that faced his industry, and how much beer could help stop that. Soon after that call, he started his own company. Today, they are the leading firm in digital female healthcare and more. He co-founded the company and spent a lot of time furthering the cause. He is making major strides in the system while receiving major plaudits as well. When asked how he brings ideas to life, he stated that all he has to do is make sure the legal financial and technical aspects are sorted out. Once the item is in public, it could stand whatever test is thrown at it. Others could be conceptualized and brought into the market, but because they don’t have the solid foundation to stand on strong other competitors could easily wipe them off the market. They could also make the product redundant. Along with this, is getting the right people to do the job. He takes part in talent acquisition and contributes a lot to get the right people in the job. For him to get the best results, the best people have to be at the helm of affairs and that is something very important to him. Something that excites him is the ability for any company in any sector to push the limits of what is acceptable. He makes mention of Tesla Motors in the automobile industry, that are now using electric motors to run their cars instead of the normal fuel engine. He predicts that things like these make companies the leader in their field of operation. Marc Beer hopes Renovia can follow in their footsteps, currently, they are the leader of women’s healthcare and also a frontrunner worldwide. Unfortunately, digital healthcare hasn’t made much progress this decade, but he hopes that future decades will bring a new face of technology that will take his company to new heights.

Marc Beer – article recap

LumeNXT announces Marc Beer as the new chairman of the board

 

LumeNXT, Inc. has announced the recruitment of Mr. Marc Beer as the new chairman of its board. Marc is a seasoned professional with more than 25 years’ experience in biotechnology, pharmaceuticals, and leadership. Marc is set to utilize his expertise to help the company achieve its goals in a timely manner.

 

LumeNXT is a privately held corporation that focuses on the development of surgical illumination products that are used in minimally invasive surgeries. LumeNXT has been at the forefront of the development of intracavity light emitting diode illumination. The advanced illumination platforms are mainly utilized by doctors to achieve more precision and efficiency in their work.

 

Compared to traditional techniques, targeted illumination enhances visualization, flexibility, and precision of the surgeon. This increases the chances of carrying out a successful procedure and ensures that it is carried out in a cost friendly and safe manner.

 

Speaking after his appointment, Marc Beer said that he was proud to be working with the dedicated and highly accomplished surgeons and engineers in LumeNXT. He praised the doctors and engineers for the various advancements that they had made to improve the LumeNXT platform. He also thanked the company and all staff for their dedication to ensuring that surgeries are conducted using minimally invasive procedures.

 

Paul Rhyne who is the co-founder of LumeNXT congratulated and praised Marc after the appointment. He also said that he had confidence in Marc and his ability to help the company meet its goals. Paul Rhyne said that Marc had already demonstrated an ability to lead by being highly successful in the various organizations that he has worked with. He also pointed out that Marc has repeatedly shown his ability to help startup companies turn a profit.

 

Marc Beer is also experienced in working with startup companies and helping them to go through the various growth phases that a company goes through smoothly. In the interview, Paul said that marc’s vast experience would help the company in the global commercial rollout and the company’s path to profitability.

 

About Marc Beer

 

Prior to joining LumeNXT, Marc had worked in several other organizations in and around the fields of biotechnology and pharmaceuticals. Marc Beer is the founding chairperson who also served as the CEO of Renovia, Inc. The company was formed to discover and deliver digital therapeutic and diagnostic kits for women suffering from pelvic floor disorders. Learn more: https://renoviainc.com/

 

Marc Beer holds a B.S from Miami University and began his early career by holding various positions in Genzyme. Genzyme is a specialty care company that works in the development of treatments for diseases that are difficult to diagnose or treat.

Mark Beer Renovia Inc. CEO

Mack Beer is a very experienced man in commercialisation and development of pharmaceuticals, devices, biotechnology, and diagnostics. He had over 25 years in the field and founded Renovia company together with Ramon Iglesias, Yolanda Lorie and MD in 2016. The company deals with lending capital funds to health care ventures.

 

In 2000 Mack Beer became the CEO of NASDAQ; VIAC which is a biotechnology company and specialises in preservation, collection and development of blood stem cells for the umbilical cord. Under his leadership, he grew the company from the start to rapidly growing and robust organisation it is today. The company has over 300 employees; it was later acquired by PerkinElmer in 2007.

 

Before becoming CEO to big organisations, Mack held different positions in his career. While CEO at ViaCell he was also serving in the board of directors at Erytec pharmaceuticals which is a public company.

 

In Genzyme, he was the vice president of global marketing. Here, he was in charge of the commercial launch of many products addressing many rare diseases around the globe. He also served in a marketing and sales position at Abbott Laboratories; Marc was also a member of Mass Life Science at commonwealth.

 

Renovia Inc. will be making new products dealing with pelvic floor disorder; the company just closed a $32 million Series B deal on Tuesday and addition of venture debt worth $10 million. The company is developing several therapeutical and diagnostic products to aid in the better treatment of pelvic floor disorders such as urinary incontinence which is common among women. Renovia had their first product in this line approved by the FDA in April.

 

Urinary incontinence is a rare type of pelvic floor disease that affects mostly women. Currently, over $250 million women around the world suffer from this disorder. Therefore, there is need for more awareness of this disorder and also better medication and better diagnostics.

 

Longwood fund, which is an investment firm that primarily focuses on health-care had invested earlier in Renovia; recently the company has joined series B round which is led by Perspective Advisers a New York-based company and Missouri-Ascension Ventures. This funding will be used for development and testing of their four new diagnostic and therapeutic products, which includes the generation of a new Leva device.

 

Mack Beer expressed his appreciation for the new support in the venture to better the diagnoses and treatment of pelvic floor disorders and hence save the lives of many women around the world. According to Marc, the combination of the two innovation and technology will help to develop a digital health programme that will provide customers with valuable data and information about new and available treatment options; this will help to drive understanding of this disorders and hence lower the healthcare cost in the long run. Learn more: https://www.bizjournals.com/boston/potmsearch/detail/submission/6457372/Marc_Beer

 

“Marc Beer Pioneering the Biotech Industry “

Marc Beer is the Chief Executive Officer of Renovia Inc. It is a pharmaceutical firm based in Boston. The firm is trying to develop a treatment for pelvic floor disorder. The disease like urinary infections affects a large percentage of women worldwide. Marc Beer founded Renovia Inc. and some of his associates. Marc Beer invested $32 million for use in coming up with new drugs for the treatment. Renovia Inc. is developing equipment and diagnosis that can be used to treat pelvic floor disorder. The firm came up with the first health care product, Leva to be used to diagnose the disease. The product got approved by the FDA a few months after it was released. Marc believes that with the correct diagnosis they can help millions of women.

Several therapeutic firms are coming together to help Renovia Inc. in developing a cure. One of these firms is the Longwood Fund that had initially invested in Renovia. Longwood Fund is an investment firm that only deals with medical institutions. Missouri-based Ascension Ventures and the New York Perspective Advisors lead the series B financing firms. The firms are funding the research on four new drugs for the treatment of pelvic floor disorder and would even like to make an upgrade of the Leva drug. Marc is delighted to be getting support from other therapeutic firms that are concerned with women’s health. The other firms are sharing the same vision as Renovia. Renova’s vision is to cure as many women as they can.

 

Marc believes that through combining ideas and technological equipment coming up with a cure will not be as difficult as it was initially. Marc is creating a platform that gives individuals a better understanding of pelvic floor disorder; its treatment options and affordable prices for patients that would like to get treatment. Marc Beer is not only the founder and CEO of Renovia Inc. but has also founded several other firms. In 2000 he founded ViaCell, a firm that collects, preserves and studies the umbilical cord stem blood cells. He led the coming to success by ensuring that there were continuous growth and profit margins.

 

Through Marc Beer’s management, the company has grown tremendously creating employment opportunities. ViaCell became publicized in 2005, and currently, PerkinElmer manages the firm. Marc is among the board of directors of various firms. He helps in making agreements on important decisions and even creates growth strategies for firms. He has worked with Genzyme and is currently working with Global Marketing as the Vice President. His principal role is to announce the launch of new products for the cure of significant diseases. Marc is also among the committee members for pharmaceutical firms that discuss significant health-related problems. Learn more: https://www.crunchbase.com/person/marc-beer